Back to Search Start Over

A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting

Authors :
Luigi Lavorgna
Teresa Costabile
Luca Carmisciano
R Lanzillo
N. Frattaruolo
Giacomo Lus
Alvino Bisecco
Alessio Signori
Simona Bonavita
A. Strianese
G. T. Maniscalco
V. Brescia Morra
Maddalena Sparaco
Elisabetta Signoriello
Simone Cepparulo
Francesco Saccà
Camilla Russo
Lanzillo, R
Sparaco, M
Lavorgna, L
Carmisciano, L
Signoriello, E
Signori, A
Costabile, T
Maniscalco, G T
Saccà, F
Cepparulo, S
Russo, C V
Bisecco, A
Frattaruolo, N
Strianese, A
Lus, G
Brescia Morra, V
Bonavita, S
Lanzillo, R.
Sparaco, M.
Lavorgna, L.
Carmisciano, L.
Signoriello, E.
Signori, A.
Costabile, T.
Maniscalco, G. T.
Sacca, F.
Cepparulo, S.
Russo, C. V.
Bisecco, A.
Frattaruolo, N.
Strianese, A.
Lus, G.
Brescia Morra, V.
Bonavita, S.
Source :
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 41(11)
Publication Year :
2019

Abstract

Background: Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS). Objective: To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS). Methods: Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group. Results: Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM. Conclusions: Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results.

Details

ISSN :
15903478
Volume :
41
Issue :
11
Database :
OpenAIRE
Journal :
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Accession number :
edsair.doi.dedup.....9739ec591cc3ed52d902202e393ec70c